本文已被:浏览 537次 下载 387次
Received:November 22, 2022 Published Online:August 20, 2023
Received:November 22, 2022 Published Online:August 20, 2023
中文摘要: 目的进一步了解未被预测模型IPSET-thrombosis纳入的促进原发性血小板增多症(ET)血栓形成的因素。方法检索PubMed、Web of Science和The Cochrane Library数据库,对292项研究进行系统评价,并计算不同因素ET患者血栓发生率及相对风险比(RR),同时对结果可信度作推荐评分(RS),结合RR值及RS分析找到ET患者血栓形成的风险因素。结果促进ET血栓形成的危险因素有9个。其中包含IPSET-thrombosis纳入的4个因素:血栓形成史(35.0%, RR=3.30, 95%CI:2.30~4.75)、JAK2V617F阳性(21.0%, RR=2.28,95%CI:1.14~4.56)、年龄大于60岁(22.4%,RR=1.95,95%CI:1.17~3.23)、心血管危险因素(CVR)(17.7%,RR=1.90, 95%CI:1.08~3.35)。以及IPSET-thrombosis未纳入的5个因素:X染色体失活模式(XCIP)的单克隆型(30.6%,RR=4.49,95%CI:1.58~12.77)、JAK2V617F高负荷(33.9%,RR=3.69,95%CI:1.70~7.99)、白细胞增多(18.7%, RR=3.05, 95%CI:1.81~5.13)、MPL突变(22.1%,RR=2.40, 95%CI:1.08~5.33)、脾肿大(25.6%, RR=1.76, 95%CI 1.29~2.40)。结论除IPSET-thrombosis评分系统纳入的4个血栓危险因素外,XCIP单克隆型、JAK2V617F高负荷、白细胞增多、MPL突变、脾肿大5个因素也是促进ET患者血栓形成的因素。
Abstract:ObjectiveTo further understand the factors that promote thrombosis in essential thrombocythemia (ET) that were not included in IPSET-thrombosis (International Prognostic Score of Thrombosis for ET). MethodsA systematic evaluation was conducted on 292 studies by retrieving PubMed,Web of Science, and The Cochrane Library. The incidence and relative risk ratio (RR) of thrombosis in ET patients with different risk factors were calculated. The confidence levels for the outcome were analyzed in combination with RR values and recommendation scores (RS) to find the thrombotic risk factors in ET patients. ResultsOut of 9 risk factors that promoted ET thrombosis, there were 4 factors in IPSET-thrombosis, including history of thrombosis (35.0%, RR=3.30, 95% CI : 2.30-4.75), JAK2V617F positive (21.0%, RR=2.28, 95%CI : 1.14-4.56), age over 60 years old ( 22.4% , RR=1.95, 95%CI : 1.17-3.23) and cardiovascular risk factors (17.7%, RR =1.90, 95%CI : 1.08-3.35). The remaining five risk factors, not listed in IPSET-thrombosis, included monoclonal type of ET based on X-chromosome inactivation pattern (XCIP, 30.6%, RR=4.49, 95% CI: 1.58-12.77), high JAK2V617F burden (33.9%, RR=3.69, 95%CI: 1.70-7.99), leukocytosis (18.7%, RR=3.05, 95%CI: 1.81-5.13), MPL mutation (22.1%, RR=2.40, 95%CI: 1.08-5.33) and splenomegaly (25.6%, RR=1.76, 95%CI:1.29-2.40). ConclusionAmong the risk factors promoting thrombosis in ET patients, five thrombotic risk factors not included in the IPSET-thrombosis have been identified.
keywords: Essential thrombocythemia Meta-analysis Thrombosis JAK2V617F mutation Splenomegaly Monoclonal type of X-chromosome inactivation pattern MPL mutation
文章编号: 中图分类号:R558.3 R551.3 文献标志码:B
基金项目:国家自然科学基金面上项目(82174360);中国中医科学院科技创新工程重大攻关项目(CI2021A01702)
引用文本: